BLOOMINGTON, Ind. -- Federal clearance to market a hydrophilic-coated version of Cook Critical Care's antimicrobial central venous catheter means U.S. clinicians now can bring Cook Spectrum's superior properties, which help provide protection against catheter-elated bloodstream infections, to patients posing the greatest catheter placement challenges.
The new Cook Spectrum Glide Minocycline/Rifampin Impregnated Catheters, which received Food and Drug Administration (FDA) clearance this month, will be marketed immediately to U.S. critical care facilities, Cook officials announced.
Cook Spectrum catheters employ the company's patented antimicrobial impregnation process that helps provide protection on both the internal and external surfaces of the catheter. Spectrum catheters have been shown to be up to 12 times more likely to resist life-threatening catheter-related infections compared to chlorhexadine/silver sulfadiazine-coated catheters. With its new, highly lubricious hydrophilic surface, Cook Spectrum Glide central venous catheters offer an unparalleled combination of patient safety and ease of use.
"With the Cook Spectrum Glide line of catheters, Cook now offers physicians the best of both worlds," explained Bruce Gingles, vice president of Cook Critical Care. "Spectrum antimicrobial catheters impregnated with minocycline and rifampin show superior results in reducing the risks to patients from catheter-related infections and sparing hospitals the enormous cost of treating these patients. Now, with Cook's unique new Spectrum Glide product, no physician will ever again need to choose between using a catheter they can place easily or using one that provides the highest level of protection against catheter-related bloodstream infection."
Source: Cook Critical Care